Kelan Thomas, PharmD, MS, BCPS, BCPP

Associate Professor, College of Pharmacy


Improving mental health care through psychiatric clinical pharmacy and research, with a knowledge base in psychopharmacology, pharmacogenomics and psychedelic-assisted psychotherapy.


  • Master of Science, Clinical Research, University of Michigan, 2009
  • Doctor of Pharmacy, Pharmaceutical Sciences, University of California, San Francisco, 2007
  • Bachelor of Science, Chemistry with Pharmacology, Duke University, 2002 

Honors and Awards

  • WIRED Magazine Top 10 Scientific Breakthroughs of 2009


Psychedelic-assisted therapy adverse effects and drug-drug interactions

Recent Publications

-Malcolm, B., Thomas, K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (2021). Online ahead of print:

-Cohen IV, Makunts T, Abagyan R, Thomas K. Concomitant drugs associated with increased mortality for
MDMA users reported in a drug safety surveillance database. Sci Rep. 2021;11(1):5997.

-Thomas KL, Malcolm, BJ. Adverse Effects, In: Grob CS & Grigsby J, Editors. Handbook of Medical
Hallucinogens, pp. 414-440, Guilford Press: New York, 2021.

-Thomas K, Muzyk AJ. Surveys of substance use disorders education in US pharmacy programs. Ment Health
Clin. 2018;8(1):14-17.

-Van Dyke P, Thomas KL. Concomitant calcium channel blocker and antipsychotic therapy in patients with
schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data. Ann Clin Psychiatry. 2018;30(1):6-16.

-Thomas KL, Doroudgar, S. Lithium, In: Ray SD, Editor. Side Effects of Drugs Annual: A worldwide yearly
survey of new data in adverse drug reactions, Vol. 39, pp. 23-30, Elsevier: Cambridge, 2017.

-Dopheide JA, Bostwick JR, Goldstone LW, Thomas K, Nemire R, Gable KN, Cates M, Caballero J, Smith T,
Bainbridge J. Curriculum in psychiatry and neurology for pharmacy programs. AJPE. 2017;81(7): Article 5925.

-Muzyk AJ, Peedin E, Lipetzky J, Parker H, McEachern MP, Thomas K. Substance use education in US schools
of pharmacy: A systematic review of the literature. Subst Abus. 2017;38(4):455–463.

-Thomas K, Malcolm B, Lastra D. Psilocybin-assisted therapy: a review of a novel treatment for psychiatric
disorders. J Psychoactive Drugs. 2017;49(5):446-455.

-Doroudgar S, Chuang HM, Perry PJ, Thomas K, Bohnert K, Canedo J. Driving performance comparing older
versus younger drivers. Traffic Inj Prev. 2017;18(1):41-46.

-Ray SD, Thomas KL, Kisor DF. ADRs, ADEs and SEDs: A Bird’s Eye View, In Side Effects of Drugs
Annual: A worldwide yearly survey of new data in adverse drug reactions, Vol. 38, pp. xxvii-xli, Elsevier:
Cambridge, 2016.

-Maroney ME, Liu MT, Smith T, Thomas KL. Lithium, In: Ray SD, Editor. Side Effects of Drugs Annual: A
worldwide yearly survey of new data in adverse drug reactions, Vol. 38, pp. 21-28, Elsevier: Cambridge, 2016.

-Thomas KL, Canedo J, Perry PJ, Doroudgar S, Lopes I, Chuang HM, Bohnert K. Effects of valerian on
subjective sedation, field sobriety testing and driving simulator performance. Accid Anal Prev. 2016;92:240-4.

-Nguyen L, Thomas KL, Lucke-wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: An
update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1-22.

-Thomas KL, La A, Punia S, Doroudgar S, Perry P. Valproic acid-induced hyperammonemia and minimal
hepatic encephalopathy prevalence among psychiatric inpatients. Ann Clin Psychiatry. 2016;28(1):37-42.

-Perry PJ, Fredriksen K, Chew S, Ip EJ, Lopes I, Doroudgar S, Thomas KL. The effects of dextromethorphan
on driving performance and the standardized field sobriety test. J Forensic Sci. 2015;60(5):1258-62.

-Thomas KL, Jiang Y, McCombs JS. Clozapine revisited: Impact of clozapine vs olanzapine on health care use
by schizophrenia patients on Medicaid. Ann Clin Psychiatry. 2015;27(2):90-9.

-English BA, Thomas KL, Johnstone J, Bazih A, Gertsik L, Ereshefsky L. Use of translational
pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. Biomark Med. 2014;8(1):29-49.

-English BA, Thomas KL, Gertsik L, Ereshefsky L. Early phase drug development strategies to inform decision
making and the viability of novel CNS compounds in schizophrenia. JCS. 2013;5(4):34-9.

-English BA, Ereshefsky L, Thomas KL, Jhee S. Improving transition of investigational medicines in
alzheimer’s disease from phase 1 to phase 2. JCS. 2013;5(1):52-9.

-Bly MJ, Bishop JR, Thomas KL, Ellingrod VL. P-glycoprotein (PGP) polymorphisms and sexual dysfunction
in female patients with depression and SSRI-associated sexual side effects. J Sex Marital Ther. 2013;39(3):280-

-Thomas KL, Ellingrod VL, Bishop JR, Keiser MJ. A pilot study of the pharmacodynamic impact of SSRI drug
selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel
pharmacogenetic approach. Psychopharmacol Bull. 2010;43(1):11-22.

-Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB,
Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular
targets for known drugs. Nature. 2009;462(7270):175-81.

-Ellingrod VL, Bishop JR, Thomas KL. Pharmacogenomics of Psychiatry. In Pharmacogenomics: Applications
to Patient Care, Second Edition. ACCP: Kansas City, 2009.

-Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse
drug reactions. Pharmacotherapy. 2009;29(7):822-31.

Memberships and Affiliations

International Society for Research on Psychedelics (ISRP)

College of Psychiatric and Neurologic Pharmacists (CPNP)

Teaching Responsibilities

PRMC 610: Pharmaceutical Sciences 3, PRMC 612: Clinical Sciences 3 (Course Coordinator), PRMC 616: Clinical Sciences 4